tbc-11251 has been researched along with clazosentan in 1 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (clazosentan) | Trials (clazosentan) | Recent Studies (post-2010) (clazosentan) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 94 | 33 | 61 |
| Protein | Taxonomy | tbc-11251 (IC50) | clazosentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.175 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolli, MH; Boss, C; Gatfield, J | 1 |
1 review(s) available for tbc-11251 and clazosentan
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |